NetworkNewsBreaks – CymaBay Therapeutics, Inc. (NASDAQ: CBAY) Closes $144M Public Offering
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) recently announced the closing of a public offering of 13.34 million shares, including the sale of additional 1,740,000 shares of common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. The common stock public offering was part of a bid to fund the ongoing development of its drug Seladelpar, a treatment for autoimmune liver disease, primary biliary cholangitis (“PBC”) and nonalcoholic steatohepatitis (“NASH”). The company sold the shares at an offering price of $10.80 per share resulting in the gross proceeds of approximately $144 million prior to underwriting discounts and…







